The FDA published its quality management maturity (QMM) recommendation when there was a severe shortage of drugs because of a lack of quality products being developed and marketed by pharmaceutical companies. Through the QMM recommendation, companies are expected to demonstrate a deep understanding of their products (both legacy and new), and not just from a system maturity point of view.
Sanjay stressed that to acquire this deep understanding, pharma companies must develop a methodology to bring their legacy products up to par with the quality standards imposed on newer products. They can do this by re-examining the role of continuous process verification (CPV) to manage their legacy products and process knowledge, from development through commercialization to discontinuation.
“There is a false perception that annual product review (APR) and CPV are one and the same. But APR is just a subset of CPV,” Sanjay said. “CPV is a broader concept because it gives you a more holistic picture of overall product performance over a period of time. While both APR and CPV give you an indication of product performance, the current situation in most companies is that they remain disconnected. We have an opportunity to improve and align them, but this can only happen through digitalizing the entire process,” he stated.
Sanjay covered a variety of relevant and timely CPV-related topics, including:
Sanjay is a pharmaceutical industry leader with more than 21 years of experience developing, launching, and maintaining drug supply. His results-oriented approach and application of technically sound pharmaceutical manufacturing science have enabled some of the largest organizations deliver on critical revenue targets. Sanjay worked in several Indian and MNC pharmaceutical firms namely Cipla, Dr Reddy’s Laboratories, Sandoz, Watson, Zydus and Torrent. He currently heads technology transfer and process development at Lupin.
Process, product performance and comparability are key to global production. This is how to support global manufacturing of pharma products.
By Rui Almeida
Read
This current era of biopharmaceutical manufacturing is a most challenging and exciting time for our industry. Technology breakthroughs, intensifying competition, and continually rising performance expectations from patients, stakeholders, pressure from government bodies for cost reduction, and regulators necessitate rapid change in execution.
By Dr. Alton Johnson
Read
Stage 3, CPV, encompasses validation maintenance or verification that the qualified cleaning process continues to perform consistently.
By Igor Gorsky
Read